Antisense oligonucleotide therapeutics, of the type that could be developed to target lncRNAs, include fomivirsen, which was used to treat cytomegalovirus retinitis [90] before being superceded by newer therapies, tofersen, which inhibits translation of superoxide dismutase in amytrophic lateral sclerosis [91] and eteplirsen, which causes exon skipping in the dystrophin transcript, used in therapy of Duchenne muscular dystrophy [92]. The gene discussed is DMD; the disease is cytomegalovirus retinitis.